Market value drops by 6% on concerns that new lung cancer drug may not be as successful as hoped
Nearly £10bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.
Shares in the Anglo-Swedish pharmaceutical company fell by as much as 6% on Monday morning after it published the first results from its phase 3 trial for datopotamab deruxtecan, making it the biggest faller among FTSE 100 companies.
